The Latest Cardiac and Vascular News
* Core revenue on a constant currency basis, non-GAAP EPS, non-GAAP net income, non-GAAP operating margin, non-GAAP gross margin and free cash flow are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures is included under […]
SAN FRANCISCO, April 23, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the appointment of Renee Budig to its Board of Directors effective April 23, 2020. Ms. Budig was appointed as a Class II […]
IRVINE, Calif., April 23, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2020. First Quarter Results and Outlook Sales grew nearly 14% to $1.1 billion TAVR sales grew 24%; underlying1 sales grew 25% […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its Serranator® PTA Serration Balloon Catheter for treating below-the-knee (BTK) lesions. The Serranator device is the first and only angioplasty balloon FDA Cleared and CE Marked that embeds serration technology into a […]
EDEN PRAIRIE, Minn., April 23, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has shipped the first commercial orders of its next generation Aquadex SmartFlow™ system to Austria, following shipments to […]
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, today announced that it has entered into definitive agreements with several institutional and accredited […]
A Statement from the Heart Failure Society of America ROCKVILLE, Md., April 23, 2020 /PRNewswire/ — The COVID-19 pandemic presents an unprecedented crisis for patients, clinicians, and healthcare systems. Most US healthcare systems have reduced ambulatory outpatient clinics – pillars of the longitudinal care of patients with chronic illnesses. In this context, […]
– Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences – Separately, total PAH-related patient healthcare costs are 67% higher for selexipag in article published in Drugs – Real World Outcomes SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, […]
PORTLAND, Ore., April 23, 2020 /PRNewswire/ — VisCardia Inc., a privately held medical device developer, announced today it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its implantable VisONE® system designed for the treatment of moderate to severe heart failure with reduced ejection fraction and preserved ventricular […]
Alliance and Equity Investment Improves Access to Remote Patient Care for 70 Percent of the Global Population MOUNTAIN VIEW, Calif. and KYOTO, Japan, April 23, 2020 /PRNewswire/ — AliveCor, a leader in personal ECG products, and OMRON Healthcare, Co., Ltd., a global leader in personal heart health and wellness technology, today announced a global, strategic alliance […]
